Novel Targets for the Development of Monoclonal Antibodies for Immunotherapy)
NCT06842407 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2025-02-24
Summary
The first objective of the project consists in the preclinical validation of new possible molecular targets associated with intratumoral T regulatory cells. The second objective consists in the selection of monoclonal antibodies with therapeutic potential, specific for the selected targets.
Conditions
- Healthy Donors
Sponsors & Collaborators
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
collaborator OTHER -
Checkmab S.r.l.
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2023-04-01
- Primary Completion
- 2026-06-30
- Completion
- 2026-06-30
Countries
- Italy
Study Locations
More Related Trials
-
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
NCT02978274 ·Status: UNKNOWN
-
Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors
NCT04268368 ·Status: UNKNOWN
-
T Cell Response in Hypersensitivity Syndrome
NCT00213447 ·Status: COMPLETED
-
In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides
NCT02159937 ·Status: COMPLETED
-
Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy
NCT03434912 ·Status: UNKNOWN
-
Early Detection of Complications During Immunotherapy for Haematological Malignancy
NCT06377059 ·Status: RECRUITING ·Phase: NA
-
Phase I Study of OriC902 in Treatment of Advanced HCC
NCT06891742 ·Status: RECRUITING ·Phase: PHASE1
-
GI Complications in Cancer Immunotherapy Patients
NCT02784366 ·Status: UNKNOWN
-
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
NCT06783270 ·Status: RECRUITING ·Phase: PHASE1
-
Dendritic Cell Vaccination for Patients with Solid Tumors
NCT01291420 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
NCT06900296 ·Status: NOT_YET_RECRUITING
-
Functional Plasticity of Human IL-17-producing CD8+ T Cells
NCT03291639 ·Status: COMPLETED
-
Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors
NCT05976906 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19
NCT04324996 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors
NCT03047811 ·Status: UNKNOWN ·Phase: NA
-
Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders
NCT03123458 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Trial of Vaccine Therapy With mRNA- Transfected Dendritic Cells in Patients With Advanced Malignant Melanoma
NCT01278940 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
NCT06509490 ·Status: RECRUITING ·Phase: NA
-
NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts
NCT04960059 ·Status: COMPLETED
-
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands
NCT02203825 ·Status: COMPLETED ·Phase: PHASE1
-
Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1
NCT02840058 ·Status: COMPLETED ·Phase: NA
-
COVID-2019 Vaccine Immune Response Base on Single Cell Multi-Omics
NCT04871932 ·Status: RECRUITING
-
NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
NCT05131763 ·Status: UNKNOWN ·Phase: PHASE1
-
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL)
NCT01611142 ·Status: COMPLETED ·Phase: PHASE2
-
To Identify HLA-A1101-restricted Peptide Epitopes Derived From Novel Oncoantigens (URLC10, KIF20A, and CDCA1) Applicable for Cancer Vaccine in Singapore
NCT01570439 ·Status: UNKNOWN